Didier Le Normand

Didier Le Normand graduated from the ESLSCA Paris business school (F) and holds a MBA degree from Pace University NY (USA). After a start of his career in banking, both United States and France, he moved to industrial corporate environments. Now he has a 20 year CFO experience, Finance and Operations, for private equity and venture backed private and listed companies in Europe, particularly in the Technology and Healthcare sectors. Over the past ten years Didier worked for Novagali Pharma (listed ophthalmic Biotech sold to Santen Pharma Japan), Cellnovo (listed Medtech, diabetes management systems) and, in his previous role, for STAT-DX (Spanish private medical diagnostic, successful sale to Qiagen in April 2018).

Didier Le Normand is the Chief Financial Officer at Minoryx Therapeutics, based in Europe. With a background in Biotechnology, Didier Le Normand has a rich history of leadership and innovation.Didier Le Normand studied Master's degree in business administration Finance and international business at Lubin School of Business. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.